| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/14/2002 | WO2002020519A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | WO2002020513A1 Oxindole derivatives |
| 03/14/2002 | WO2002020512A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 03/14/2002 | WO2002020511A1 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 03/14/2002 | WO2002020510A1 Acid-sensitive compounds, preparation and uses thereof |
| 03/14/2002 | WO2002020501A2 Polyarylcarboxamides useful as lipid lowering agents |
| 03/14/2002 | WO2002020495A2 Inhibitors of glycogen synthase kinase 3 |
| 03/14/2002 | WO2002020494A1 Process for producing pyrimidine derivative and intermediate thereof |
| 03/14/2002 | WO2002020489A2 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/14/2002 | WO2002020488A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | WO2002020485A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/14/2002 | WO2002020483A1 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 03/14/2002 | WO2002020465A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | WO2002020457A1 Dihydroxy open-acid salt of simvastatin |
| 03/14/2002 | WO2002020088A1 Method and system for myocardial infarction repair |
| 03/14/2002 | WO2002020056A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 03/14/2002 | WO2002020055A1 Remedies for heart failure |
| 03/14/2002 | WO2002020034A1 'pseudo'-native chemical ligation |
| 03/14/2002 | WO2002020033A1 Polymer-modified synthetic proteins |
| 03/14/2002 | WO2002020030A2 Use of buchu extracts for hypertension |
| 03/14/2002 | WO2002020024A1 Purine ribosides as antiarrhythmics |
| 03/14/2002 | WO2002020003A2 Use of carp inhibitors for the treatment of heart diseases |
| 03/14/2002 | WO2002019966A2 Cardiac arrhythmia treatment methods |
| 03/14/2002 | WO2002019963A2 Synthetic erythropoiesis stimulating proteins |
| 03/14/2002 | WO2002019894A2 Methods for analyzing and using data from hypertensive patients |
| 03/14/2002 | WO2002019837A1 Improved bioactive whey protein hydrolysate |
| 03/14/2002 | WO2001090189A3 G-protein coupled receptor org3. |
| 03/14/2002 | WO2001077147A3 New bromodomain protein |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001070668B1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 03/14/2002 | WO2001068612A3 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 03/14/2002 | WO2001066543A3 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 03/14/2002 | WO2001066093A3 Sustained release ranolazine formulations |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001064668A3 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 03/14/2002 | WO2001062737A3 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 03/14/2002 | WO2001058921A9 Methods and compositions for generating angiostatin |
| 03/14/2002 | WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils |
| 03/14/2002 | WO2001057085A3 G-protein coupled receptors |
| 03/14/2002 | WO2001055358A3 Phosphodiesterases |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001051512A3 Human and parasite orphan receptor proteins |
| 03/14/2002 | WO2001044497A3 Protein kinase regulation |
| 03/14/2002 | WO2001030327A3 Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of ischaemic conditions |
| 03/14/2002 | WO2001023572A3 Polynucleotides and polypeptides encoded thereby |
| 03/14/2002 | WO2001020031A3 Polymorphisms in a klotho gene |
| 03/14/2002 | WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 03/14/2002 | WO2000053742A9 Polynucleotides and proteins encoded thereby |
| 03/14/2002 | US20020032332 Hypotensive agents, antiallergens, antiasthma, treating bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorder, gastrointestinal motility or cardiovascular disorders |
| 03/14/2002 | US20020032306 Cyclopeptide derivatives |
| 03/14/2002 | US20020032229 Novel compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032214 Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound |
| 03/14/2002 | US20020032212 A tricyclic compound (with oxy and nitrogen atoms in the ring); perticularly useful for treating or preventing psoriasis and other skin diseases |
| 03/14/2002 | US20020032210 Chloride channel blockers; useful in the treatment of sickle cell anaemia, brain edema following iscaemia or tumors, diarrhea, hypertension, bone metabolic disorders, osteoclast associated disoders; substituted biphenyl containing nitrogen |
| 03/14/2002 | US20020032208 Chemical compounds |
| 03/14/2002 | US20020032205 An alkyl amine substituted isobenzofuran compound useful for certain psychiatric and neurological disorders; potently binding to the 5-HT1A receptor |
| 03/14/2002 | US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor |
| 03/14/2002 | US20020032199 5-HT7 receptor antagonists |
| 03/14/2002 | US20020032196 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032194 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032192 Treatment of vasodilatory headache |
| 03/14/2002 | US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors |
| 03/14/2002 | US20020032174 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 03/14/2002 | US20020032167 Increasing dwell time of fluid in a targeted area, administration of vascular permeablizing agent, and administration of a viral vector containing a gene expression cassette of interest |
| 03/14/2002 | US20020032157 Methods of inhibiting ectopic calcification |
| 03/14/2002 | US20020032151 Using an agent which promotes tyrosine protein dephosphorylation in the preparation of a medicament for reducing permeability of a physiological barrier such as the blood-brain barrier |
| 03/14/2002 | US20020031508 Administering inducer of P-selectin activity such that hemostasis occurs |
| 03/14/2002 | DE10043667A1 2-Guanidino-4-aryl-chinazoline 2-guanidino-4-aryl-quinazolines |
| 03/14/2002 | DE10043124A1 Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase Method for the diagnosis of neural disorders and for the treatment of primary hemostasis deficiency |
| 03/14/2002 | DE10042997A1 Thienopyrimidine Thienopyrimidines |
| 03/14/2002 | DE10042137A1 sgk2 und sgk3 als diagnostische und therapeutische Targets sgk2 and sgk3 as diagnostic and therapeutic targets |
| 03/14/2002 | DE10041402A1 Neue Verbindungen, die Faktor Xa-Aktivität inhibieren Novel compounds which inhibit factor Xa activity |
| 03/14/2002 | DE10040901A1 Neue Phenyl- und Phenylalkyl-substituierte Ethanolamine und Ethylendiamine New phenyl and phenylalkyl substituted ethanolamines and ethylenediamines |
| 03/14/2002 | DE10028575A1 Integrinliganden Integrin |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2431711A1 Remedies for heart failure |
| 03/14/2002 | CA2425912A1 Use of buchu extracts for hypertension |
| 03/14/2002 | CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421834A1 Use of carp inhibitors for the treatment of heart diseases |
| 03/14/2002 | CA2421714A1 Improved bioactive whey protein hydrolysate |
| 03/14/2002 | CA2421584A1 Gene therapy for cardiac arrythmias |
| 03/14/2002 | CA2421451A1 Method and system for myocardial infarction repair |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421374A1 Methods and compositions for diseases associated with amyloidosis |
| 03/14/2002 | CA2421285A1 Methods for analyzing and using data from hypertensive patients |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421251A1 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | CA2421213A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2421179A1 Acid-sensitive compounds, preparation and uses thereof |
| 03/14/2002 | CA2421172A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | CA2421041A1 Caveolin peptides and their use as therapeutics |